Filtered By:
Procedure: Lung Transplant

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 372 results found since Jan 2013.

Prognostic Value of Pressure-Volume Measures in Hemocompatibility-Related Clinical Adverse Events
Continuous-flow left ventricular assist device (cf-LVADs) can lead to hemocompatibility-related clinical adverse events (HRAEs) which are largely determined by mechanisms that underpin the pump-patient interaction. We assessed the association of pressure-volume (PV) measures [stroke work (SW)& pump arterial elastance (EA)] with incidence of HRAEs.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: A. Gunawan, D. Robson, A. Ramanayake, R.J. Krishnaswamy, K. Kearney, K. Muthiah, P. Jain, A. Adji, C.S. Hayward Tags: (220) Source Type: research

Postoperative Atrial Fibrillation in Lung Transplant Recipients with and without Concomitant Modified Maze
Atrial fibrillation is common following lung transplantation and may contribute to increased risk of stroke. The goal of this study was to characterize the incidence of atrial fibrillation in lung transplant recipients with and without a concomitant modified Maze procedure.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: Y. Xia, S. Patel, S. Lee, R. Villamater, R. Biniwale, A. Ardehali Tags: (633) Source Type: research

Stroke Risk in the Contemporary Era of Left Ventricular Assist Device Support
The HeartMate 3 left ventricular assist device (LVAD) has lower stroke rates compared to the HeartMate 2 in a clinical trial setting. Here we report real world stroke rates in patients implanted with HeartMate 2 and HeartMate 3 LVADs.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: J. Leonard, A. Shaaban, A.C. Agdamag, Z. Jedeon, R. John, F. Kamdar, V. Maharaj, R. Cogswell Tags: (119) Source Type: research

Protein Biomarkers Predict Risk of Gastrointestinal Bleeding in Left Ventricular Assist Device Patients
This study aims to assess the validity of these biomarkers in predicting the incidence of stroke or GIB in LVAD recipients.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: K. Cavallo, M. Kanwar, G. Diao, S.S. Sinha, R. Singh, D. Tang, I. Isseh, J. Brocious, P. Bagchi, D. Crandall, D.J. Farrar, S. Murali, J. Walenga, J. Lindenfeld, C. deFilippi, P. Shah Tags: (115) Source Type: research

Sex-Based Differences in Clinical Outcomes of Stroke Related to LVAD
Sex-based differences among patients with left ventricular assist devices (LVAD) having stroke are uncertain. We aimed to compare demographic and clinical characteristics, inpatient outcomes, and measures of health care utilization among men and women who had stroke while undergoing LVAD implantation.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: M. Kassi, A.M. Minhas, S.U. Khan, A. Shah, R. Yousafzai, A. Guha, A. Bhimaraj Tags: (358) Source Type: research

Association of Outflow Cannula Angulation with Adverse Neurological Events in Patients with CF-LVAD
Adverse neurological outcomes are the Achilles heel of the current day LVAD technology and are associated with worse survival. Our previous data suggests that outflow cannula (OFC) angles measured using cardiac CT may correlate with stroke in continuous-flow HeartMate II patients. Therefore, the aim of our study was to assess the relationship of inflow cannula (IFC) and outflow cannula (OFC) position with neurological outcomes centrifugal flow pumps (HM3 and HVAD).
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: M. Kassi, S. Ingram, T. Garg, M. Chavez, M. Khan, A. Shah, R. Thaker, E. Graviss, N. Duc, A. Guha, E. Suarez, A. Bhimaraj Tags: (53) Source Type: research

Reservoir Pressure Analysis in Group 2 Pulmonary Hypertension
In this study we aim to describe Pres in Group 2 isolated post-capillary (IPC) and combined pre and post-capillary (CPC) pulmonary hypertension (PH).
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: I. Yim, K. Parker, S. Lim Tags: (307) Source Type: research

Bacteriophage Therapy and the Biofilm: An Old Solution for a Persistent and Desperate Problem?
With the adoption of use of continuous-flow pumps with centrifugal design and complete magnetic levitation (i.e., HeartMate 3, Abbott, Chicago, IL), outcomes following durable left ventricular assist device (LVAD) have continuously improved over the last five years (1). Improved hemocompatibility associated with this device design has translated into a significant reduction in major adverse events, primarily pump thrombosis, stroke, and to a lesser extent, reduction in non-surgical bleeding (1).
Source: The Journal of Heart and Lung Transplantation - February 14, 2022 Category: Transplant Surgery Authors: Pierre-Emmanuel Noly, Francis D. Pagani Tags: Editorial Source Type: research

Controlled temperatures in cold preservation provides safe heart transplantation results
ConclusionUsing the SherpaPak system during heart transplantation is safe and not associated with significant recipient morbidity. None of the recipients experienced significant PGD and mortality.
Source: Journal of Cardiac Surgery - January 21, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Macit Bitargil, Osama Haddad, Si M. Pham, Rohan M. Goswami, Parag C. Patel, Samuel Jacob, Magdy M. El ‐Sayed Ahmed, Juan Carlos Leoni Moreno, Daniel S. Yip, Kevin Landolfo, Basar Sareyyupoglu Tags: ORIGINAL ARTICLE Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin
Cardiovascular disease (CVD) as defined by the American Heart Association includes ischaemic heart disease, stroke, heart failure and thromboembolism [1]. Solid organ transplantation is associated with an increased risk of CVD morbidity and mortality [2], a relationship which was first observed in the context of kidney transplantation by Foley in 1998 [3]. This manifests clinically as an increased rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction, non-fatal stroke, unstable angina and heart failure [4,5].
Source: Heart, Lung and Circulation - November 27, 2021 Category: Cardiology Authors: Afolarin A. Otunla, Kumaran Shanmugarajah, Maria Lucia Madariaga, Alun H. Davies, Joseph Shalhoub Tags: Editorial Source Type: research

How will AI affect radiologist productivity?
Artificial intelligence (AI) software can offer much value in radiology. Bu...Read more on AuntMinnie.comRelated Reading: Radiologists boost AI severity quantification of COVID-19 Report: Reimbursement drives adoption of AI software for stroke Can AI help detect cancer on CT lung cancer screening exams? Can AI help screen for early interstitial lung disease on x-rays? CT radiomics helps predict spontaneous intracerebral hemorrhage
Source: AuntMinnie.com Headlines - November 18, 2021 Category: Radiology Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Peripheral microvascular dysfunction is associated with plaque progression and adverse long ‐term outcomes in heart transplant patients
ConclusionsPeripheral endothelial dysfunction is associated with increased plaque progression and adverse long-term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation.
Source: ESC Heart Failure - September 12, 2021 Category: Cardiology Authors: Ilke Ozcan, Takumi Toya, Michel T. Corban, Ali Ahmad, Lilach O. Lerman, Sudhir S. Kushwaha, Amir Lerman Tags: Original Research Article Source Type: research